Press Releases
Proteostasis Therapeutics Announces Presentation at the UK Cystic Fibrosis Conference
Details for the presentation are as follows:
Title: Access and the Unmet Need: Novel CFTR Modulator Combinations are Coming
Presenter: Marija Zecevic, Ph.D., Chief Commercial Officer
Session Title: Development of new therapies for cystic fibrosis
Date and time: Thursday, September 26, 2019 from
Location: Kia Oval
A live audio webcast of the UKCFC presentation will be available on the Investor Events page in the Investors & Media section of the Company's website, www.proteostasis.com. A replay of the webcast will be available on the Company's website following the presentation.
For more information on this meeting, visit: https://www.cysticfibrosis.org.uk/the-work-we-do/conference-and-meetings/ukcfc
About
Safe Harbor
To the extent that statements in this release are not historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "aim," "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements made in this release include, without limitation, statements regarding the expected presentation at an upcoming conference. Forward-looking statements made in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we, therefore cannot assure you that our plans, intentions, expectations or strategies will be attained or achieved. Such risks and uncertainties include, without limitation, the potential of our proprietary combination therapies for the treatment of CF, the potential benefit of our proprietary combination therapies to patients, expected timing of patient enrollment in, data from, the completion of, our clinical studies and cohorts for our clinical programs, including our planned Phase 2 program and initiation of a pivotal study, the possibility final or future results from our drug candidate trials (including, without limitation, longer duration studies) do not achieve positive results or are materially and negatively different from or not indicative of the preliminary results reported by the Company (noting that these results are based on a small number of patients and small data set), uncertainties inherent in the execution and completion of clinical trials (including, without limitation, the possibility that
CONTACTS:
Investors:
Argot Partners
212.600.1902
david@argotpartners.com / claudia@argotpartners.com
Media:
Argot Partners
212.600.1902
david.rosen@argotpartners.com
View original content:http://www.prnewswire.com/news-releases/proteostasis-therapeutics-announces-presentation-at-the-uk-cystic-fibrosis-conference-300922010.html
SOURCE